Microneedles embedded in a patch deliver cancer immunotherapy treatment directly to the site of melanoma, according to preliminary findings in animal studies.
Treatment with lapatinib and trastuzumab before surgery and chemotherapy led to significant shrinkage or disappearance of the tumors in approximately 25% of women with HER2-positive breast cancer.
Cyclin D1/CDK4 inhibitor treatment overcame resistance to targeted therapy in transgenic mouse models, cell cultures, and human tissue samples of HER2-positive breast cancer.
Limited radiotherapy effective after low-risk tumors are removed, but questions remain.
An exploration of the interaction between the protein produced by the common cancer-causing KRAS gene and the AGO2 protein may lead to the possibility of interrupting the KRAS-AGO2 interaction as a possible therapy.
Two distinct causes of HER2 activation in lung cancer were demonstrated in a recent study. These findings imply that HER2-positive lung cancer may need different targeted therapies to combat these related but possibly distinct diseases.
Tumor growth may be substantially slowed by the novel therapy 177Lutetium-DOTATATE (Lutathera), according to early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors.
The metabolism of pancreatic cancer cells is altered by the anticancer activity of CDK4/6 inhibitors. Researchers hope this biologic vulnerability could be exploited to treat pancreatic cancer.
Dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations have been suggested by the largest analysis of breast cancer cell function to date.
Using xenograft mice as avatars of patients with melanoma, scientists demonstrated that a previously ineffective targeted drug may halt disease progression in certain patients.
Findings of the randomized, phase 3 METEOR trial demonstrate progression-free survival in patients with advanced renal cell carcinoma is improved with cabozantinib compared with everolimus.
Lung cancers with KRAS-related gene mutations might benefit from a triple therapy regimen of 2 experimental drugs plus radiation therapy.
Palbociclib, a new oral treatment for certain types of breast cancer, demonstrates potential as a treatment for other types of cancer as well.
Researchers identified a protein that is essential for MYC to cause cancer in mouse models, and they believe, could be a target for anticancer therapy.
Mandatory tumor tissue specimens and associated analyses for clinical trial participation appear to be a significant barrier to clinical trial enrollment and may delay treatment.
The evolution of drug resistance in a patient with lung cancer was demonstrated in a recent case. In the case, molecular analysis of a metastatic lesion revealed resistance to a third targeted therapy; however, the new mutation restored tumor response to the first targeted therapy used.
Findings from a recently published study point to the enzyme casein kinase 1δ (CK1δ), a critical regulator of growth, as a novel and highly vulnerable therapeutic target in hard-to-treat subtypes of breast cancer.
Certain drugs currently used to treat breast, ovarian, and pancreatic cancers could also be used to treat certain gastric cancers with a particular genomic molecular fingerprint.
Researchers identified two new cancer-causing gene mutations that could lead to more targeted and effective treatments for certain lung and prostate cancers.
Genome sequencing database provides easy access to information on clinically important cancer gene mutationsSeptember 25, 2015
Researchers designed an online database, the Cancer Driver Log (CanDL) to help oncologists and other health care professionals identify key mutations that drive tumor growth in tissues.
Scientists have discovered that magnetic resonance imaging (MRI) scanners, normally used to produce images, can be used direct tumor therapies to specific target sites.
Results are in from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.
New research has identified as few as nine genetic features would need to be tested to identify high-risk patients who might benefit from intensive myeloma treatment.
A new tool predicts what genetics are truly driving the cancer in any population of cells and helps the user choose the best kinase inhibitor to address the issue.
Targeted therapy for skin cancer is effective in patients with sonic hedgehog (SHH) subtype of medulloblastomaAugust 26, 2015
A targeted therapy already used to treat advanced skin cancer has also been found to be effective when used to treat the most common subtype of adult medulloblastoma.
A diet that starves triple-negative breast cancer cells of an essential nutrient primes the cancer cells to be more easily killed by targeted treatment.
New research indicates that treating patients with esophageal cancer with proton therapy produces fewer toxic side effects than utilizing older radiation therapies.
Researchers have reported safely using immune cells grown from patients' own bone marrow to treat multiple myeloma, according to clinical trial data.
Two new targeted treatments slow progression of chronic-lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.
Researchers have quantified the mutational profiles for cell clusters in individual colorectal cancer tumors that have metastasized.
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Total Weight Lost Is More Important Than Type of Diet in Reversing Obesity-Cancer Link
- Navigator-specific Interventions and Multidisciplinary Care Team Collaboration Improves Care and Outcomes for Patients with GI Cancers
- Survival Prolonged by Continuing Ceritinib Beyond Disease Progression in Non-small Cell Lung Cancer
- Higher Vitamin D Levels Lower Risk of Cancer in Women
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Acupuncture Improves Management of Hot Flashes, Quality of Life in Breast Cancer
- Getting Started: Implementation of an Oncology Navigation Program That Meets Community Needs
- Beyond Treatment: Anticipating the Late Effects of Cancer Treatment in Survivors
- Light Exposure Improves Depressive Symptoms and Circadian Rhythms in Cancer Survivors
- Retooled Patient Medication Education in Oncology Improves HCAHPS Survey Scores
- Immune-stimulating Drug and Chemotherapy Show Early Promise for Pancreatic Cancer
- Patient Satisfaction Improves With Nurse-led Response to Patient Feedback
- Including Information on Breast Reconstruction Options Help Women Make Better Treatment Decisions
- Many Hold Incorrect Beliefs About FDA Approval Standards and Breakthrough Therapies
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|